S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

3 Crypto Stocks for Bitcoin Bulls to Buy Now

Tuesday, August 10, 2021 | Sean Sechler
3 Crypto Stocks for Bitcoin Bulls to Buy NowAlthough cryptocurrencies such as Bitcoin have taken investors on a wild ride in 2021, these intriguing digital assets continue to attract attention and have been recovering nicely from the large sell-off from earlier this year. Bitcoin, in particular, has been looking better in recent weeks as it rallied above the $40,000 mark and is close to reclaiming its 200-day moving average. This could lead to more upside for companies with bitcoin exposure, as they tend to trade in tandem with the price action of the leading cryptocurrencies.

While some traders might be hesitant to increase their exposure to cryptocurrencies at this time given the potential for crypto tax amendments in the upcoming U.S. infrastructure bill, the way that many of the most popular crypto stocks are performing in the market could help to ease those concerns. These companies offer an attractive way to gain exposure to cryptocurrencies through equities and could be poised for strong outperformance in the coming weeks.

That’s why we’ve put together a quick list of 3 crypto stocks for bitcoin bulls to buy now. Keep reading below to learn more.

Coinbase (NASDAQ:COIN)

First, we have Coinbase, a name that likely needs no introduction for investors that are familiar with cryptocurrencies. As the largest cryptocurrency exchange in the United States, this is a company that is a true powerhouse in the industry and has plenty of growth potential as digital currencies continue to gain traction in the financial world. What’s interesting here is that Coinbase generates transaction revenue and fees every time a user invests, spends, sends, or receives crypto assets on its platform. That means as trading volume increases so does the company’s revenue, which is why it's such an intriguing stock for bitcoin bulls.

If you didn’t purchase Coinbase after its high-profile IPO, now might be a good time to add shares as the stock appears to have bottomed in May and is currently breaking out of its post-IPO base. There’s also a lot to like about the company’s upside potential if it can diversify its revenue and create more offerings for institutional investors. Coinbase will deliver its eagerly anticipated Q2 earnings results on August 10th, which could be another strong catalyst for the stock to look out for.

Silvergate Capital Corp (NYSE:SI)

Cryptocurrencies are fascinating because they are literally creating an entirely new financial ecosystem. That’s a strong reason to consider Silvergate Capital stock, as it’s the leading provider of innovative financial infrastructure solutions and services in the digital currency industry. The company has designed the Silvergate Exchange Network, which is a network of digital currency exchanges and digital currency investors that enables the movement of cryptocurrencies like Bitcoin and can clear transactions in U.S. dollars.

If you are bullish on the prospects of Bitcoin and believe that institutional demand for cryptocurrencies is only going to increase in the future, it makes a lot of sense to add shares of this company. With 771 institutional customers and counting, Silvergate’s network is growing fast and attracting plenty of new clients. Keep in mind that as deposits grow, the company will benefit from more interest income and revenue over the long term. In Q2, Silvergate Capital reported a net income of $20.9 million, up 64.5% year-over-year, and accepted an impressive $4.3 billion in new deposits. The Silvergate Exchange Network also handled $239.6 billion in U.S. dollar transfers in Q2, up 44% year-over-year, and is confirmation that the company is experiencing record volumes at this time.

Square (NYSE: SQ)

I’ve previously mentioned why Square is a great fintech stock to own for the long-term, which includes the company’s strategic move into traditional banking services, tons of momentum with the company’s Cash App service, and big upside if it can expand internationally. However, another strong reason to consider adding shares, particularly if you are a bitcoin bull, is the fact that Square has invested significant capital in bitcoin and is one of the first major public companies to hold the cryptocurrency on its balance sheet. Square CEO Jack Dorsey is one of the most prominent bitcoin bulls, and his actions speak volumes about how big of a role the company could eventually play in the crypto economy.

There’s a lot to like about how Square allows customers to send and receive bitcoin on its Cash App without paying any transaction fees, which is certainly appealing to retail crypto enthusiasts. The company also generated $2.72 billion in Bitcoin revenue in Q2, up about 3x year-over-year, and continues to make exciting new moves to expand its product portfolio. With the stock trading right around all-time highs, Square could be a great way to play both the crypto rally and the rise of decentralized finance.
7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022

One year ago, investors expected 2021 to be a huge year for pharmaceutical stocks. The bullish perspective was that as vaccines rolled out and the economy reopened, investors would shift from biotech stocks to traditional pharmaceutical stocks.

But the Delta variant has kept Covid-19 top of mind for many investors. While it’s true that some pharmaceutical stocks were part of the vaccine race, other players in the space have not performed as well as was hoped. Case in point, as of October 6, 2021, the iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is up only 9.7% in the last 12 months. And if you bought shares of the fund at the beginning of the year, you have no growth to show for your patience.

There are reasons beyond Covid-19 to consider when assessing the disappointing performance of pharmaceutical stocks. One is the current political climate which is making no secret of its desire to reshape the healthcare industry. And it has the pricing practices of “big pharma” firmly in its crosshairs.

However, the pharmaceutical sector is still loaded with quality stocks for investors who are willing to accept the inherent risk. And that’s the focus of this special presentation. In the next few minutes, we’ll take a look at seven pharmaceutical stocks that are ready to make strong moves forward in 2022.

View the "7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022".


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.